About This Trial
Novel vaccine targeting conserved regions of coronaviruses to provide broad protection against future variants and related viruses.
Primary Endpoints
- Cross-reactive antibody response
- T-cell immunity breadth
Latest Update
February 2026
Phase 1 data demonstrated robust cross-neutralizing antibodies against SARS-CoV-1, SARS-CoV-2 variants, and MERS-CoV.
Lead Investigators
DK
Dr. Kathrin Jansen Former Head of Vaccine R&D